{
    "2019-05-06": [
        [
            {
                "time": "2019-05-06",
                "original_text": "Health Care Sector Update for 05/06/2019: ESPR, AXSM, CANF, JNJ, PFE, ABT, MRK, AMGN",
                "features": {
                    "keywords": [
                        "Health Care Sector",
                        "Update",
                        "ESPR",
                        "AXSM",
                        "CANF",
                        "JNJ",
                        "PFE",
                        "ABT",
                        "MRK",
                        "AMGN"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-05-07",
                "original_text": "Sanofi (SNY) Ex-Dividend Date Scheduled for May 07, 2019",
                "features": {
                    "keywords": [
                        "Sanofi",
                        "Ex-Dividend",
                        "Date",
                        "Scheduled"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-05-06",
                "original_text": "Pfizer Gets FDA Approval for $225,000 Heart Disease Drug",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "FDA",
                        "Approval",
                        "Heart",
                        "Disease",
                        "Drug"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-05-06",
                "original_text": "U.S. FDA Approves VYNDAQEL® and VYNDAMAX™ for Use in Patients with Transthyretin Amyloid Cardiomyopathy, a Rare and Fatal Disease",
                "features": {
                    "keywords": [
                        "U.S.",
                        "FDA",
                        "Approves",
                        "VYNDAQEL®",
                        "VYNDAMAX™",
                        "Transthyretin",
                        "Amyloid",
                        "Cardiomyopathy",
                        "Rare",
                        "Fatal",
                        "Disease"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-05-06",
                "original_text": "Conatus' (CNAT) Earnings, Revenues Miss Estimates in Q1",
                "features": {
                    "keywords": [
                        "Conatus",
                        "Earnings",
                        "Revenues",
                        "Miss",
                        "Estimates",
                        "Q1"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}